Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.
The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell.
The company was incorporated in 2014 and is based in Waltham, Massachusetts.
Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 10, 24 | -0.33 Increased by +62.92% | -0.27 Decreased by -22.22% |
| Mar 22, 24 | -1.10 Increased by +51.97% | -0.54 Decreased by -103.70% |
| Nov 13, 23 | -0.29 Increased by +75.83% | -0.76 Increased by +61.84% |
| Aug 14, 23 | -1.05 Increased by +34.38% | -0.78 Decreased by -34.62% |
| May 15, 23 | -0.89 Increased by +55.50% | -1.07 Increased by +16.82% |
| Mar 31, 23 | -2.29 Increased by +41.28% | -1.31 Decreased by -74.81% |
| Nov 8, 22 | -1.20 Increased by +14.29% | -1.47 Increased by +18.37% |
| Aug 12, 22 | -1.60 Decreased by -33.33% | -1.72 Increased by +6.98% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by -100.00% | -10.95 M Decreased by -282.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 6.00 K Decreased by -91.89% | -19.13 M Increased by +24.59% | Decreased by -318.80 K% Decreased by -830.07% |
| Sep 30, 23 | 31.00 K Decreased by -35.42% | -5.72 M Increased by +45.53% | Decreased by -18.46 K% Increased by +15.66% |
| Jun 30, 23 | 31.00 K Increased by +72.22% | -16.52 M Decreased by -17.19% | Decreased by -53.29 K% Increased by +31.96% |
| Mar 31, 23 | 35.00 K Decreased by -32.69% | -2.87 M Increased by +82.97% | Decreased by -8.19 K% Increased by +74.70% |
| Dec 31, 22 | 74.00 K Increased by +362.50% | -25.36 M Increased by +14.76% | Decreased by -34.28 K% Increased by +81.57% |
| Sep 30, 22 | 48.00 K Increased by +65.52% | -10.51 M Increased by +6.72% | Decreased by -21.89 K% Increased by +43.64% |
| Jun 30, 22 | 18.00 K Decreased by -88.39% | -14.10 M Decreased by -54.18% | Decreased by -78.32 K% Decreased by -1.23 K% |